

# Synthesis of Fully Functionalised Spiropyran Pyrazolone Skeletons *via* formal [4+2] Cascade Process Using $\beta$ -Nitro Styrene Derived MBH-Alcohols

Yeruva Pavankumar Reddy <sup>a</sup> and Shaik Anwar <sup>\*a</sup>

<sup>a</sup>Department of Chemistry, School of Applied Sciences and Humanities, Vignan's Foundation for Science Technology and Research-VFSTR (Deemed to be University), Vadlamudi-522213, Guntur, Andhra Pradesh, India, Tel: (+91)-8632344700; E-mail: [shaikanwarcu@gmail.com](mailto:shaikanwarcu@gmail.com); [drsa\\_sh@vignan.ac.in](mailto:drsa_sh@vignan.ac.in)  
<http://www.vignan.ac.in/bshanwar.php>

## Supporting Information


<b>Contents</b>	<b>S1</b>
<b>Experimental Section</b>	<b>S2- S5</b>
<b>Compounds Characterisation</b>	<b>S6-S12</b>
<b>NMR Spectra</b>	<b>S13-S43</b>
<b>Crystal Data</b>	<b>S44-S46</b>
<b>References</b>	<b>S47</b>

## Experimental Section

### General


All reactions were carried out with dry, freshly distilled solvents in anhydrous conditions. Thin-layer chromatography (TLC) was performed on silica gel plates (60F-254) using UV-light (254 and 365 nm). Flash chromatography was performed on silica gel (230–400 mesh). NMR (400 MHz for  $^1\text{H}$  NMR, and  $^{13}\text{C}$  NMR) spectra were recorded in  $\text{CDCl}_3$  with TMS as the internal standard. Chemical shifts are reported in ppm and coupling constants are given in Hz. Data for  $^1\text{H}$  NMR are recorded as follows: chemical shift (ppm), multiplicity (s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet, coupling constant (Hz), integration. Data for  $^{13}\text{C}$  NMR are reported in terms of chemical shift ( $\delta$ , ppm). High-resolution mass spectra (HRMS) were recorded on micro mass ESI-TOF MS. Melting points were determined in a Hanon auto melting point system (MP 450). IR was recorded on FTIR Bruker Technologies. HPLC chromatogram was recorded on Shimadzu LC-20AT using chiral cell OD-H column.

### General procedure for the synthesis spiropyrazolone tetrahydropyran using primary alcohol **3**:




To a solution of arylidene pyrazolone **1** (100 mg, 0.381 mmol, 1.0 equiv.) was added nitro allylic primary alcohol **2** (102 mg, 0.572 mmol, 1.5 equiv.) and  $\text{K}_2\text{CO}_3$  (131 mg, 0.952 mmol, 2.5 equiv.) in  $\text{CH}_3\text{CN}$  (2 mL). The reaction mixture was stirred at room temperature till the completion reaction. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure. The resulted crude was subjected to flash column chromatography on silica gel (200-400) by eluting ethyl acetate in hexane (4:96) to afford the desired products **3a**.

**General procedure for the synthesis of spiropyrazolone teterhydropyran using secondary alcohol 5:**




To a solution of arylidene pyrazolone **1** (100 mg, 0.38 mmol, 1.0 equiv.) was added nitro allylic secondary alcohol **4** (143 mg, 0.57 mmol, 1.5 equiv.) and  $\text{Cs}_2\text{CO}_3$  (310 mg, 0.95 mmol, 2.5 equiv.) in  $\text{CHCl}_3$  (2 mL). The reaction mixture was stirred at room temperature till the completion reaction. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure. The resulted crude was subjected to flash column chromatography on silica gel (200-400) by eluting ethyl acetate in hexane (4:96) to afford the desired products **5**.

**General procedure for the synthesis of chiral tetrahydrochromene 3a using thiourea catalyst:**




To a solution of arylidene pyrazolone **1** (50 mg, 0.190 mmol, 1.0 equiv.) was added nitro allylic primary alcohol **2** (51 mg, 0.286 mmol, 1.5 equiv.) and 10 mol% of quinine derived thiourea catalyst in  $\text{CH}_3\text{CN}$  (1.5 mL). The reaction mixture was stirred at room temperature till the completion reaction. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure. The resulted crude was subjected to flash column chromatography on silica gel (200-400) by eluting ethyl acetate in hexane (4:96) to afford the desired products **3a**. We have performed HPLC chromatogram by using chiral cel OD-H column to furnished **3a** as 94% of enantiomeric excess using IPA:Hex (20:80).

### General procedure for the synthesis of nitro styrene derived MBH-primary alcohol<sup>1</sup>:




To a stirred solution of nitrostyrene in dry THF as a solvent, imidazole and anthranilic acid was added to the reaction mixture at room temperature. The reaction was allowed to stir at room temperature for 15 min. Then add drop wise addition of formaldehyde to the reaction mixture was allowed to stir at rt for 12h. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The formation of crude was separated by column chromatography by the combination of (6:94%) ethyl acetate and hexane.

### General procedure for the synthesis of nitro styrene derived MBH-secondary alcohol<sup>2</sup>:




To a stirred solution of Nitrostyrene in dry THF as a solvent, imidazole and DMAP was added to the reaction mixture at room temperature. The reaction was allowed to stir at room temperature for 15min. Then add drop wise addition of ethylglyoxylate to the reaction mixture was allowed to stir at rt for 4h. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The formation of crude was separated by column chromatography by the combination of (7:93%) ethyl acetate and hexane.

### General procedure for the synthesis of unsaturated arylidene pyrazolone<sup>3</sup>:




To a stirred solution of pyrazolone in acetic acid as a solvent, sodium acetate and benzaldehyde was added to the reaction mixture at room temperature. The reaction was allowed to stir at room temperature for 3 h. After the completion of the reaction, the organic layer was extracted with ethyl acetate, washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The formation of crude was separated by column chromatography by the combination of (4:96%) ethyl acetate and hexane.

## In-situ Raman spectroscopy analysis for reaction mechanism:




To a solution of arylidene pyrazolone **1** (30 mg, 0.09 mmol, 1.0 equiv.) was added nitro allylic primary alcohol **2** (17 mg, 0.09 mmol, 1.0 equiv.) and  $\text{K}_2\text{CO}_3$  (30 mg, 0.09 mmol, 1.0 equiv.) in  $\text{CH}_3\text{CN}$  (1 mL) at room temperature. The reaction mixture was stirred at room temperature for 5 min and cooled to  $-60\text{ }^\circ\text{C}$ . to the cooled reaction mixture benzyl bromide (21  $\mu\text{l}$ , 0.18 mmol, 2.0 equiv.) the reaction mixture was allowed stirr at the same temperature until the disappearance of keto group (monitored by Raman spectroscopy).

### Before addition of benzyl bromide ( $\text{C}=\text{O}$ )




### After addition of benzyl bromide ( $\text{C}=\text{O}$ missing)



## Compounds Characterisation

### 4-methyl-9-nitro-2,6,10-triphenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3a):

Compound **3a** was synthesized according to the general procedure by taking **1a** (100 mg, 0.381 mmol, 1.0 equiv.), **2a** (102 mg, 0.572 mmol, 1.5 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid: 93% (157.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3019, 2956, 1699, 1526, 1096, 779.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.32-7.29 (m, 3H), 7.28-7.18 (m, 11H), 7.14-7.10 (m, 1H), 5.76-5.69 (m, 1H), 5.12 (s, 1H), 5.09-5.06 (m, 1H), 4.91-4.87 (m, 1H), 4.44 (d, *J* = 12.4 Hz, 2H), 4.26 (t, *J* = 10.8 Hz, 1H), 2.40 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 170.7, 157.5, 136.5, 134.5, 128.7, 128.5, 128.2, 125.8, 125.2, 124.2, 120.1, 114.3, 83.4, 81.3, 71.1, 66.7, 55.6, 19.1.

HRMS calcd. C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub>, 442.17668; found 442.17651 [M + H]

### 6-(2,4-dichlorophenyl)-4-methyl-9-nitro-2,10-diphenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3b):

Compound **3b** was synthesized according to the general procedure by taking **1b** (100 mg, 0.302 mmol, 1.0 equiv.), **2a** (102 mg, 0.572 mmol, 1.5 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid; Yield: 71% (110.0 mg).

**IR** (neat, cm<sup>-1</sup>) 2923, 2896, 1701, 1524, 1096, 715, 821.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.49-7.34 (m, 1H), 7.33-7.30 (m, 1H), 7.28-7.16 (m, 10H), 7.13-7.06 (m, 1H), 5.79-5.75 (m, 1H), 5.54 (s, 1H), 4.48 (dd, *J* = 28.0, 8.0 Hz, 1H), 4.86 (d, *J* = 12.8 Hz, 1H), 4.29 (t, *J* = 10.8 Hz, 1H), 2.60 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 169.1, 156.7, 136.4, 135.8, 134.5, 131.8, 131.0, 129.9, 129.0, 128.7, 128.5, 127.6, 127.1, 125.9, 119.6, 80.3, 70.6, 63.9, 50.0, 24.6, 19.9.

HRMS calcd. C<sub>26</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub>, 510.09874; found 510.09812 [M + H]

#### 4-methyl-9-nitro-2,6-diphenyl-10-(p-tolyl)-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3c):

Compound **3c** was synthesized according to the general procedure by taking **1** (100 mg, 0.381 mmol, 1.0 equiv.), **2c** (110 mg, 0.57 mmol, 1.5 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid; Yield: 57% (98.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3021, 2923, 1696, 1548, 1093, 827.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.25-7.22 (m, 6H), 7.21-7.15 (m, 3H), 7.13-7.10 (m, 3H), 7.02 (d, *J* = 8.0 Hz, 2H), 5.74-5.66 (m, 1H), 5.07 (s, 1H), 4.87 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.40 (d, *J* = 12.4 Hz, 1H), 4.24 (t, *J* = 10.8 Hz, 1H), 2.20 (s, 3H), 2.39 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 170.7, 157.5, 138.6, 136.5, 134.8, 129.6, 129.1, 128.6, 128.2, 127.3, 125.8, 125.2, 120.0, 83.5, 81.0, 70.1, 65.5, 20.9, 19.1.

HRMS calcd. C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub>, 456.19233; found 457.19231 [M + H]

#### 10-(4-methoxyphenyl)-4-methyl-9-nitro-2,6-diphenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3d):

Compound **3d** was synthesized according to the general procedure by taking **1** (100 mg, 0.381 mmol, 1.0 equiv.), **2d** (119 mg, 0.572 mmol, 1.0 equiv. K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid; Yield: 61% (106.0 mg).

**IR** (neat, cm<sup>-1</sup>) 2885, 2811, 1699, 1597, 1114, 831, 711.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.26-7.25 (m, 5H), 7.22-7.20 (m, 4H), 7.17 (d, *J* = 8.8 Hz, 2H), 7.14-7.10 (m, 1H), 6.74 (d, *J* = 8.8 Hz, 2H), 5.70-5.63 (m, 1H), 5.10 (s, 1H), 4.86 (dd, *J* = 5.2, 11.2, Hz, 1H), 4.38 (d, *J* = 12.8 Hz, 1H), 4.24 (t, *J* = 10.8 Hz, 1H), 3.68 (s, 3H), 2.39 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 170.8, 159.6, 157.5, 136.5, 134.9, 128.7, 128.6, 128.2, 125.9, 125.2, 124.0, 120.1, 114.3, 83.5, 70.1, 65.6, 55.1, 49.0, 19.1.

HRMS calcd. C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub>, 472.18725; found 472.18712

**10-(4-(benzyloxy)phenyl)-4-methyl-9-nitro-2,6-diphenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3e):**

Compound **3e** was synthesized according to the general procedure by taking **1** (100 mg, 0.381 mmol, 1.0 equiv.), **2e** (163 mg, 0.572 mmol, 1.5 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid: 57% (98.0 mg)

**IR** (neat, cm<sup>-1</sup>) 3052, 2921, 1701, 1523, 1126, 812.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.39-7.37 (m, 4H), 7.34-7.10 (m, 13H), 6.81 (d, *J* = 8.8 Hz, 2H), 5.70-5.63 (m, 1H), 5.10 (s, 1H), 4.92 (s, 2H), 4.86 (dd, *J* = 4.8, 10.8, Hz, 1H), 4.38 (d, *J* = 12.4 Hz, 1H), 4.24 (t, *J* = 10.8 Hz, 1H), 2.39 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 170.8, 158.9, 157.5, 136.5, 136.4, 134.9, 128.7, 128.6, 128.5, 128.2, 127.9, 127.4, 125.9, 125.2, 124.4, 120.1, 115.2, 83.5, 81.2, 70.1, 65.6, 49.0, 29.6, 19.1.

HRMS calcd. C<sub>33</sub>H<sub>29</sub>N<sub>3</sub>O<sub>5</sub>, 547.21072; found 547.21071 [M + H]

**4-1-methyl-9-nitro-4-oxo-3,6-diphenyl-7-oxa-2,3-diazaspiro[4.5]dec-1-en-10-yl)benzonitrile (3f):**

Compound **3f** was synthesized according to the general procedure by taking **1** (100 mg, 0.381 mmol, 1.0 equiv.), **2f** (116 mg, 0.572 mmol, 1.0 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid; Yield: 71% (110.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3064, 2924, 1707, 1594, 1097, 821.

**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.38 (d, *J* = 6.0 Hz, 1H), 7.36-7.21 (m, 10H), 7.19-7.10 (m, 3H), 5.43-5.37 (m, 1H), 5.20-5.18 (m, 2H), 4.87 (dd, *J* = 11.2, 4.8 Hz, 1H), 4.33 (t, *J* = 10.8 Hz, 1H), 2.53 (s, 3H).


**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 169.5, 156.3, 136.4, 135.3, 134.5, 130.7, 128.9, 128.7, 128.3, 128.2, 127.3, 125.8, 125.3, 119.6, 83.4, 82.2, 69.9, 64.4, 29.6, 20.0.

HRMS calcd. C<sub>27</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>, 467.17193; found 468.17165 [M + H]



**6-(2,4-dichlorophenyl)-4-methyl-9-nitro-2-phenyl-10-(p-tolyl)-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3g):**

Compound **3g** was synthesized according to the general procedure by taking **1b** (100 mg, 0.302 mmol, 1.0 equiv.), **2c** (120 mg, 0.453 mmol, 1.5 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid; Yield: 55% (95.0 mg).

**IR** (neat, cm<sup>-1</sup>) 2923, 2854, 1709, 1499, 1091, 818, 663,


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, *J* = 2.0 Hz, 1H), 7.30-7.26 (m, 3H), 7.25-7.22 (m, 2H), 7.19-7.09 (m, 4H), 7.02 (d, *J* = 8.4 Hz, 2H), 5.78-5.71 (m, 1H), 5.53 (s, 1H), 4.81 (dd, *J* = 10.8, 5.2 Hz, 1H), 4.45 (d, *J* = 12.8 Hz, 1H), 4.28 (t, *J* = 10.8 Hz, 1H), 2.59 (s, 3H), 2.21 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 169.2, 156.8, 138.8, 136.5, 135.7, 134.4, 131.0, 129.9, 129.9, 129.7, 128.8, 128.7, 128.5, 127.4, 127.0, 125.8, 119.6, 80.9, 70.6, 64.0, 49.6, 29.6, 20.9, 19.9.

HRMS calcd. C<sub>27</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub>, 524.11439; found 524.11412 [M + H]

**10-(4-(benzyloxy)phenyl)-6-(2,4-dichlorophenyl)-4-methyl-9-nitro-2-phenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3h):**

Compound **3h** was synthesized according to the general procedure by taking **1b** (100 mg, 0.302 mmol, 1.0 equiv.), **2e** (129 mg, 0.453 mmol, 1.0 equiv.), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.952 mmol, 2.5 equiv.) in CH<sub>3</sub>CN (2 mL).



Yellow gummy solid: 77% (121.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3025, 2952, 1705, 1569, 1145, 668, 812.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.60 (d, *J* = 8.4 Hz, 1H), 7.43-7.30 (m, 10H), 7.24 (d, *J* = 8.8 Hz, 2H), 7.18 (t, *J* = 7.6 Hz, 1H), 7.12-7.09 (m, 1H), 6.82 (d, *J* = 8.4 Hz, 2H), 6.31-6.24 (m, 1H), 5.47 (s, 1H), 4.94 (s, 2H), 4.80 (dd, *J* = 11.2, 5.2, Hz, 1H), 4.15 (t, *J* = 10.8 Hz, 1H), 3.95 (d, *J* = 11.6 Hz, 1H), 2.27 (s, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 171.2, 159.2, 156.6, 136.6, 136.4, 135.9, 133.1, 131.0, 130.6, 129.5, 129.2, 128.8, 128.5, 128.0, 127.5, 127.4, 126.0, 124.4, 119.8, 115.3, 80.9, 70.5, 69.9, 63.0, 48.9, 29.6, 22.6.

HRMS calcd. C<sub>33</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>, 614.12495; found 614.12517 [M - H]

**6-(2,4-dichlorophenyl)-10-(4-methoxyphenyl)-4-methyl-9-nitro-2-phenyl-7-oxa-2,3-diazaspiro[4.5]dec-3-en-1-one (3i):**

Compound **3i** was synthesized according to the general procedure by taking **1b** (100 mg, 0.302 mmol, 1.0 equiv.), **2d** (127 mg, 0.453 mmol, 1.5 equiv.),  $K_2CO_3$  (131 mg, 0.952 mmol, 2.5 equiv.) in  $CH_3CN$  (2 mL).



Yellow gummy solid: 68% (106.0 mg).

**IR** (neat,  $cm^{-1}$ ) 2921, 2854, 1698, 1547, 1097, 820, 661,


**$^1H$  NMR** (400 MHz,  $CDCl_3$ )  $\delta$  7.59 (d,  $J = 8.4$  Hz, 1H), 7.41-7.39 (m, 2H), 7.33-7.29 (m, 3H), 7.22 (d,  $J = 8.8$  Hz, 2H), 7.17 (t,  $J = 7.2$  Hz, 1H), 7.10 (dd,  $J = 8.8, 2.4$  Hz, 1H), 6.74 (d,  $J = 8.8$  Hz, 2H), 6.30-6.23 (m, 1H), 5.46 (s, 1H), 4.80-4.76 (m, 1H), 4.15 (t,  $J = 10.8$  Hz, 1H), 3.94 (d,  $J = 11.6$  Hz, 1H), 3.70 (s, 3H), 2.26 (s, 3H).

**$^{13}C$  NMR** (100 MHz,  $CDCl_3$ )  $\delta$  171.9, 159.6, 136.6, 135.9, 128.7, 128.6, 127.5, 125.9, 125.3, 123.0, 120.1, 114.3, 83.5, 81.3, 71.1, 64.6, 55.1, 49.1, 19.1.

HRMS calcd.  $C_{27}H_{24}Cl_2N_3O_5$ , 540.10930; found 540.10912 [ $M + H$ ].

**6-(2,4-dichlorophenyl)-1-methyl-9-nitro-4-oxo-3-phenyl-7-oxa-2,3-diazaspiro[4.5]dec-1-en-10-yl)benzotrile (3j):**

Compound **3j** was synthesized according to the general procedure by taking **1b** (100 mg, 0.302 mmol, 1.0 equiv.), **2f** (92 mg, 0.453 mmol, 1.5 equiv.),  $K_2CO_3$  (131 mg, 0.952 mmol, 2.5 equiv.) in  $CH_3CN$  (2 mL).



Yellow gummy liquid; Yield: 76% (119.0 mg).

**IR** (neat,  $cm^{-1}$ ) 2923, 2853, 1727, 1545, 1102, 689, 784.


**$^1H$  NMR** (400 MHz,  $CDCl_3$ )  $\delta$  7.57-7.52(m, 2H), 7.47-7.41 (m, 2H), 7.39- 7.33(m, 5H), 7.21 (t,  $J = 7.6$  Hz, 1H), 7.12-7.08 (m, 2H), 6.28-6.21 (m, 1H), 5.54 (s, 1H), 4.78 (m, 2H), 4.23 (t,  $J = 10.8$  Hz, 1H), 2.30 (s, 3H).

**$^{13}C$  NMR** (100 MHz,  $CDCl_3$ )  $\delta$  171.0, 156.8, 136.4, 136.1, 135.6, 135.2, 133.3, 130.6, 130.5, 130.3, 129.4, 128.9, 128.2, 127.6, 126.2, 119.5, 118.4, 80.5, 70.3, 62.6, 43.8, 29.6, 15.7.

HRMS calcd.  $C_{27}H_{21}Cl_2N_4O_4$ , 535.09399; found 535.09312.

**Ethyl-1-methyl-9-nitro-4-oxo-3,6,10-triphenyl-7-oxa-2,3-diazaspiro[4.5]dec-1-ene-8-carboxylate (5a):**

Compound **5a** was synthesized according to the general procedure by taking **1** (100 mg, 0.38 mmol, 1.0 equiv.), **4a** (143 mg, 0.57 mmol, 1.5 equiv.), Cs<sub>2</sub>CO<sub>3</sub> (310 mg, 0.95 mmol, 2.5 equiv.) in CHCl<sub>3</sub> (2 mL).



Yellow gummy liquid; Yield: 78% (153.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3024, 2931, 1704, 1541, 1078, 812.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.43-7.26 (m, 6H), 7.22-7.16 (m, 3H), 7.12-7.10 (m, 3H), 7.08 (d, *J* = 6.8 Hz, 1H), 6.8 (d, *J* = 9.2 Hz, 2H), 6.30-6.24 (m, 1H), 5.47 (s, 1H), 4.80-4.76 (m, 1H), 4.51 (t, *J* = 13.6 Hz, 3H), 4.39 (d, *J* = 29.2 Hz, 1H), 4.30 (q, *J* = 8.0 Hz, 2H), 2.27 (s, 1H), 1.27 (t, *J* = 3.6 Hz, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 169.2, 159.7, 156.6, 136.4, 135.6, 133.1, 131.6, 131.0, 128.9, 128.8, 128.7, 128.5, 127.6, 127.1, 125.9, 119.6, 80.6, 80.3, 70.6, 63.9, 50.1, 24.4, 19.9, 14.1.

HRMS calcd. C<sub>30</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>, 514.19781; found 514.19692 [M + H]

**Ethyl 6-(2,4-dichlorophenyl)-1-methyl-9-nitro-4-oxo-3-phenyl-10-(p-tolyl)-7-oxa-2,3-diazaspiro[4.5]dec-1-ene-8-carboxylate (5b):**

Compound **5b** was synthesized according to the general procedure by taking **1** (100 mg, 0.302 mmol, 1.0 equiv.), **4b** (120 mg, 0.453 mmol, 1.5 equiv.), Cs<sub>2</sub>CO<sub>3</sub> (310 mg, 0.95 mmol, 2.5 equiv.) in CHCl<sub>3</sub> (2 mL).



Yellow gummy liquid; Yield: 60% (108.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3021, 2986, 1699, 1521, 1156, 714, 779.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, *J* = 8.0 Hz, 2H), 7.38-7.28 (m, 3H), 7.23-7.09 (m, 5H), 7.03 (d, *J* = 7.6 Hz, 2H), 5.72-5.65 (m, 1H), 5.59 (s, 1H), 4.95 (d, *J* = 10.0 Hz, 1H), 4.44 (d, *J* = 12.4 Hz, 1H), 4.31 (q, *J* = 8.4 Hz, 2H), 2.66 (s, 3H), 2.21 (s, 3H), 1.27 (t, *J* = 3.6 Hz, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 168.7, 156.6, 139.4, 139.1, 136.4, 136.1, 136.0, 134.5, 133.0, 130.8, 130.4, 129.7, 129.2, 128.7, 128.4, 128.1, 127.7, 127.2, 126.0, 125.8, 82.7, 79.5, 62.8, 62.6, 50.7, 22.6, 21.0, 14.1.

HRMS calcd. C<sub>30</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>6</sub>, 596.13552; found 596.13492 [M + H]

**Ethyl-1-methyl-9-nitro-4-oxo-3,6,10-triphenyl-7-oxa-2,3-diazaspiro[4.5]dec-1-ene-8-carboxylate (5c):**

Compound **5c** was synthesized according to the general procedure by taking **1** (100 mg, 0.302 mmol, 1.0 equiv.), **4c** (127 mg, 0.453 mmol, 1.0 equiv.), Cs<sub>2</sub>CO<sub>3</sub> (310 mg, 0.95 mmol, 2.5 equiv.) in CHCl<sub>3</sub> (2 mL).



Yellow gummy liquid; Yield: 56% (105.0 mg).

**IR** (neat, cm<sup>-1</sup>) 3024, 2652, 1702, 1521, 1067, 667, 812.


**<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.97 (d, *J* = 8.0 Hz, 2H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.42-7.37 (m, 4H), 7.34-7.28 (m, 3H), 7.18-7.16 (m, 2H), 6.64-5.62 (m, 1H), 5.31 (d, *J* = 6.4 Hz, 2H), 5.19-5.07 (m, 1H), 4.28 (q, *J* = 6.8 Hz, 2H), 3.91 (s, 3H), 2.12 (s, 3H), 1.26 (t, *J* = 3.6 Hz, 3H).

**<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 169.2, 158.0, 156.8, 138.8, 136.6, 135.7, 134.4, 131.1, 129.9, 129.6, 128.8, 128.6, 128.4, 127.4, 127.0, 125.8, 119.6, 80.9, 80.3, 70.6, 64.0, 55.0, 49.6, 29.6, 20.9, 19.9, 14.9.


**HRMS** calcd. C<sub>30</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>7</sub>, 612.13043; found 612.13026 [*M* + *H*]

Sample Code: PKR-32

PKR-32




Plotname: PKR-32\_PROTON\_20220819\_01\_plot01




<sup>1</sup>H NMR Spectrum of compound 3a

Solvent: cdcl3  
SA-AGILENT 400MHz NMR  
Date: Aug 2 2022



<sup>13</sup>C NMR Spectrum of compound 3a  
S14




Plotname: PFR-32-N-13C-NMR-CARBON\_20220808\_01\_plot01

# HPLC chromatogram for racemic compound of **3a**

## ==== Shimadzu LCsolution Analysis Report ====


D:\YPKREDDY\313 res10% ipa-hex OD-H pyrazole1.lcd  
Acquired by : Admin  
Sample Name : 313 res10% ipa-hex OD-H pyrazole  
Sample ID : 313 res10% ipa-hex OD-H pyrazo  
Vail # : 0  
Injection Volume : 20 uL  
Data File Name : 313 res10% ipa-hex OD-H pyrazole1.lcd  
Method File Name : pyrazole313.lcm  
Batch File Name : SingleRun120020101004312.lcb  
Report File Name : Default.lcr  
Data Acquired : 1/1/2002 12:44:32 AM  
Data Processed : 1/1/2002 3:07:38 AM

### <Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.840	15405234	566638	50.470	59.035
2	20.578	15118573	393197	49.530	40.965
Total		30523806	959835	100.000	100.000




# HPLC chromatogram for chiral compound of **3a**

# ==== Shimadzu LCsolution Analysis Report ====

D:\YPKREDDY\3rd paper data\313 chiral ipahex 14.9.2022 od1.lcd  
Acquired by : Admin  
Sample Name : 313 chiral ipahex 14.9.2022 od  
Sample ID : 313 chiral ipahex 14.9.2022 od  
Vial # : 0  
Injection Volume : 20 uL  
Data File Name : 313 chiral ipahex 14.9.2022 od1.lcd  
Method File Name : 14\_9\_2022 chiral with ncs.lcm  
Batch File Name : SingleRun120020102000725.lcb  
Report File Name : Default.lcr  
Data Acquired : 1/2/2002 12:08:14 AM  
Data Processed : 1/2/2002 1:16:00 AM


## <Chromatogram>



PeakTable

Detector A Ch1 254nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.856	121293	2997	4.153	4.935
2	25.757	2799151	57738	95.847	95.065
Total		2920443	60735	100.000	100.000





Sample Code: PKR-352



PROTON 2  
SA\_Variat\_300MHz\_NMR\_PRESSENTATION  
Date\_ Time\_ Rec\_ 2022\_AUG\_07\_16:11:33  
solvent cdcl3 wet n  
file /home/vassian/~SPECIAl  
352\_20220811\_01/PKR-352 temp 25.0  
R-352\_PROTON\_20220~ spin 40  
811.01.fid hst 0.768  
ACQUISITION pw90 12.200  
sw 7183.9 alfa 10.000  
at 4.000 FLAGS  
np 57472 il n  
fb 4000 in n  
bs 2 dp Y  
dl 1.000 hs nm  
nt 512 PROCESSING  
ct 30 lb 0.50  
tn TRANSMITTER HI fn not used  
sfrq 399.689 SP DISPLAY  
tof 799.4 WP -155.9  
tpwr 61 rFL 6530.6  
pw 6.100 rfp 793.4  
dn DECOUPLER IP -41.1  
dof 0 C13 lp 0  
dm min wc PLOT 268  
decwave W40\_GATE-0~ sc 0  
dpwr 12 vs 480  
dmf 29412 ai cdc ph 3





<sup>1</sup>H NMR Spectrum of compound **3b**

Sample Code: PKR-352-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Aug 14 2022




<sup>13</sup>C NMR Spectrum of compound **3b**




<sup>1</sup>H NMR Spectrum of compound 3c

Sample Code: 359-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Sep 15 2022




<sup>13</sup>C NMR Spectrum of compound **3c**




Sample Code: PKR-347-N

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Aug 5 2022




Plotname: PKR-347-N\_PROTON\_20220805\_01\_plot01




<sup>1</sup>H NMR Spectrum of compound 3d

Sample Code: PRR-347-N-13C-NMR

Solvent: cdcl3  
SA-AGILENT 400MHz NMR  
Date: Aug 6 2022





<sup>13</sup>C NMR Spectrum of compound **3d**



Sample Code: PKR-3-1


Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Jul 28 2022




<sup>1</sup>H NMR Spectrum of compound **3e**

Sample Code: PKR-3-1-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Jul 29 2022



<sup>13</sup>C NMR Spectrum of compound **3e**





Plotname: PKR-3-1-13C-NMR\_CARBON\_20220729\_01\_plot01



Sample Code: 358



Solvent: cdcl3  
SA-AGILENT 400MHz NMR  
Date: Sep 14 2022



<sup>1</sup>H NMR Spectrum of compound **3f**



Sample Code: 358-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHZ NMR  
Date: Sep 15 2022



<sup>13</sup>C NMR Spectrum of compound **3f**  
S26



Sample Code: EKR-351





<sup>1</sup>H NMR Spectrum of compound **3g**

Sample Code: FKR-351-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Aug 12 2022




<sup>13</sup>C NMR Spectrum of compound **3g**




<sup>1</sup>H NMR Spectrum of compound 3h


Sample Code: PKR-313-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Jun 16 2022





<sup>13</sup>C NMR Spectrum of compound **3h**






<sup>1</sup>H NMR Spectrum of compound **3i**






Plotname: EPR-331-N-13C-NMR\_CARBON\_20220808\_01\_plot01





<sup>13</sup>C NMR Spectrum of compound **3i**






<sup>1</sup>H NMR Spectrum of compound 3j







<sup>13</sup>C NMR Spectrum of compound **3j**



Sample Code: 360-13C-NMR



Solvent: cdcl3  
 SA-Varian 400MHz NMR  
 Date: Sep 15 2022



<sup>1</sup>H NMR Spectrum of compound 5a



Sample Code: PKR-355-13C-NMR

Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Aug 14 2022





<sup>13</sup>C NMR Spectrum of compound 5a

Sample Code: 361




<sup>1</sup>H NMR Spectrum of compound **5b**




<sup>13</sup>C NMR Spectrum of compound **5b**

Sample Code: PKR-365



Solvent: cdcl3  
SA-Varian 400MHz NMR  
Date: Sep 19 2022



<sup>1</sup>H NMR Spectrum of compound **5c**



Plotname: PKR-365\_PROTON\_20220919\_01\_plot01



$^{13}\text{C}$  NMR Spectrum of compound **5c**




347

Sample Name: 347 Pulse sequence: NOESY Temperature: 25 Study owner: agilent  
 Date collected: 2022-09-20 Solvent: dms0 Spectrometer: Agilent-NMR-vnmrs400 Operator: agilent

Sample Code: 347  
 NOESY 2D

Solvent: dms0  
 SA-Agilent 400MHz NMR  
 Date & Time: Wed Sep 21 12:49:28 MDT 2022





347

Sample Name: 347 Pulse sequence: NOESY Temperature: 25 Study owner: agilent  
 Date collected: 2022-09-20 Solvent: dms0 Spectrometer: Agilent-NMR-vnmrs400 Operator: agilent

Sample Code: 347  
 NOESY 2D

Solvent: dms0  
 SA-Agilent 400MHz NMR  
 Date & Time: Wed Sep 21 12:50:25 MDT 2022




NOESY Spectrum of compound **3d**

347

Sample Name: 347 Pulse sequence: NOESY Temperature: 25 Study owner: agilent  
Date collected: 2022-09-20 Solvent: dms0 Spectrometer: Agilent-NMR-vnmrs400 Operator: agilent

Sample Code: 347  
NOESY 2D

Solvent: dms0  
SA-Agilent 400MHz NMR  
Date & Time: Wed Sep 21 12:51:00 MDT 2022





347

Sample Name: 347 Pulse sequence: NOESY Temperature: 25 Study owner: agilent  
Date collected: 2022-09-20 Solvent: dms0 Spectrometer: Agilent-NMR-vnmrs400 Operator: agilent

Sample Code: 347  
NOESY 2D

Solvent: dms0  
SA-Agilent 400MHz NMR  
Date & Time: Wed Sep 21 12:51:45 MDT 2022





NOESY Spectrum of compound 3d

347

Sample Name: 347 Pulse sequence: NOESY Temperature: 25  
Date collected: 2022-09-20 Solvent: dms0 Spectrometer: Agilent-NMR-vnmrs400 Operator: agilent


Sample Code: 347  
NOESY 2D

Solvent: dms0  
SA-Agilent 400MHz NMR  
Date & Time: Wed Sep 21 12:52:03 MDT 2022



NOESY Spectrum of compound 3d

## Crystallographic data of 3a



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) KB665\_0m

This report is for guidance only. if used as part of a review procedure for publication, it should not replace the expertise of an experienced crystallographic referee.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: KB665\_0m

Bond precision: C-C = 0.0036 Å Wavelength=0.71073

Cell: a=24.734(2) b=9.6942(8) c=26.455(3) alpha=90 beta=109.097(3) gamma=90

Temperature: 293 K

Calculated Reported Volume 5994.2(10) 5994.2(9) Space group P 21/c P 21/c Hall group -P 2ybc -P 2ybc

Moiety formula

C<sub>66</sub> H<sub>54</sub> Cl<sub>4</sub> N<sub>6</sub> O<sub>10</sub>, 2(C<sub>33</sub> H<sub>27</sub> Cl<sub>2</sub> N<sub>3</sub> O<sub>5</sub>), 2(O<sub>0.67</sub>), 1.018(O)

4(C<sub>33</sub> H<sub>27</sub> Cl<sub>2</sub> N<sub>3</sub> O<sub>5</sub>), 2.36(O)

Sum formula C<sub>132</sub> H<sub>108</sub> Cl<sub>8</sub> N<sub>12</sub> O<sub>22.36</sub> Mr 2503.73 2503.67

D<sub>x</sub>, g cm<sup>-3</sup> 1.387 1.387 Z 2 2 Mu (mm<sup>-1</sup>) 0.266 0.266 F<sub>000</sub> 2597.8 2598.0 F<sub>000</sub>' 2601.32

h,k,l<sub>max</sub> 29,11,31 29,11,31 N<sub>ref</sub> 10576 10566 T<sub>min</sub>, T<sub>max</sub> 0.914, 0.943 0.632, 0.746 T<sub>min</sub>' 0.914

Correction method= # Reported T Limits: T<sub>min</sub>=0.632 T<sub>max</sub>=0.746 AbsCorr = MULTI-SCAN

Data completeness= 0.999 Theta(max)= 24.998

R(reflections)= 0.0474( 9266)

wR<sub>2</sub>(reflections)= 0.1135( 10566)

S = 1.125 N<sub>par</sub>= 910

The following ALERTS were generated. Each ALERT has the format test-name\_ALERT\_alert-type\_alert-level. Click on the hyperlinks for more details of the test.

Alert level C PLAT042\_ALERT\_1\_C Calc. and Reported MoietyFormula Strings Differ

Please Check PLAT094\_ALERT\_2\_C Ratio of Maximum / Minimum Residual Density ....

2.12 Report PLAT214\_ALERT\_2\_C Atom O1W (Anion/Solvent) ADP max/min Ratio

4.1 prolat PLAT220\_ALERT\_2\_C NonSolvent Resd 1 C U<sub>eq</sub>(max)/U<sub>eq</sub>(min) Range 3.3

Ratio PLAT242\_ALERT\_2\_C Low 'MainMol' Ueq as Compared to Neighbors of N3B  
 Check PLAT906\_ALERT\_3\_C Large K Value in the Analysis of Variance ..... 3.666 Check  
 PLAT911\_ALERT\_3\_C Missing FCF Refl Between Thmin & STh/L= 0.595 8 Report

Alert level G PLAT003\_ALERT\_2\_G Number of Uiso or Uij Restrained non-H Atoms ...  
 28 Report PLAT068\_ALERT\_1\_G Reported F000 Differs from Calcd (or Missing)... Please  
 Check PLAT083\_ALERT\_2\_G SHELXL Second Parameter in WGHT Unusually Large  
 9.52 Why ? PLAT177\_ALERT\_4\_G The CIF-Embedded .res File Contains DELU Records  
 3 Report PLAT178\_ALERT\_4\_G The CIF-Embedded .res File Contains SIMU Records 3  
 Report PLAT199\_ALERT\_1\_G Reported \_cell\_measurement\_temperature ..... (K) 293  
 Check PLAT200\_ALERT\_1\_G Reported \_diffn\_ambient\_temperature ..... (K) 293  
 Check PLAT301\_ALERT\_3\_G Main Residue Disorder .....(Resd 1 ) 19% Note  
 PLAT302\_ALERT\_4\_G Anion/Solvent/Minor-Residue Disorder (Resd 2 ) 14% Note  
 PLAT302\_ALERT\_4\_G Anion/Solvent/Minor-Residue Disorder (Resd 3 ) 100% Note  
 PLAT302\_ALERT\_4\_G Anion/Solvent/Minor-Residue Disorder (Resd 4 ) 100% Note  
 PLAT304\_ALERT\_4\_G Non-Integer Number of Atoms in ..... (Resd 3 ) 0.67 Check  
 PLAT304\_ALERT\_4\_G Non-Integer Number of Atoms in ..... (Resd 4 ) 0.51 Check  
 PLAT311\_ALERT\_2\_G Isolated Disordered Oxygen Atom (No H's ?) ..... O1D Check  
 PLAT311\_ALERT\_2\_G Isolated Disordered Oxygen Atom (No H's ?) ..... O1W Check  
 PLAT410\_ALERT\_2\_G Short Intra H...H Contact H23A ..H27D . 2.05 Ang.  
 x,y,z = 1\_555 Check PLAT767\_ALERT\_4\_G INS Embedded LIST 6 Instruction Should  
 be LIST 4 Please Check PLAT773\_ALERT\_2\_G Check long C-C Bond in CIF: C32D --  
 C33D 1.99 Ang. PLAT779\_ALERT\_4\_G Suspect or Irrelevant (Bond) Angle(s) in  
 CIF ... 34.90 Deg. C32D -C32D -H32D 3\_665 1\_555 1\_555 ..... # 164  
 Check PLAT779\_ALERT\_4\_G Suspect or Irrelevant (Bond) Angle(s) in CIF ... 28.30 Deg.  
 C33D -C32D -H32D 3\_665 1\_555 1\_555 ..... # 166 Check PLAT790\_ALERT\_4\_G  
 Centre of Gravity not Within Unit Cell: Resd. # 2 Note C33 H27 Cl2 N3 O5  
 PLAT790\_ALERT\_4\_G Centre of Gravity not Within Unit Cell: Resd. # 3 Note  
 O0.67 PLAT790\_ALERT\_4\_G Centre of Gravity not  
 Within Unit Cell: Resd. # 4 Note O  
 PLAT793\_ALERT\_4\_G Model has Chirality at C8A (Centro SPGR) S Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C8B (Centro SPGR) S Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C11A (Centro SPGR) R Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C11B (Centro SPGR) R Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C19A (Centro SPGR) R Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C19B (Centro SPGR) R Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C20A (Centro SPGR) S Verify  
 PLAT793\_ALERT\_4\_G Model has Chirality at C20B (Centro SPGR) S Verify  
 PLAT860\_ALERT\_3\_G Number of Least-Squares Restraints ..... 385 Note  
 PLAT883\_ALERT\_1\_G No Info/Value for \_atom\_sites\_solution\_primary . Please Do !  
 PLAT909\_ALERT\_3\_G Percentage of I>2sig(I) Data at Theta(Max) Still 76% Note  
 PLAT910\_ALERT\_3\_G Missing # of FCF Reflection(s) Below Theta(Min). 3 Note  
 PLAT913\_ALERT\_3\_G Missing # of Very Strong Reflections in FCF .... 1 Note  
 PLAT933\_ALERT\_2\_G Number of HKL-OMIT Records in Embedded .res File 10 Note

PLAT965\_ALERT\_2\_G The SHELXL WEIGHT Optimisation has not Converged Please Check

PLAT967\_ALERT\_5\_G Note: Two-Theta Cutoff Value in Embedded .res .. 50.0 Degree

PLAT978\_ALERT\_2\_G Number C-C Bonds with Positive Residual Density. 7 Info

PLAT992\_ALERT\_5\_G Repd & Actual \_reflns\_number\_gt Values Differ by 2 Check

0 ALERT level A = Most likely a serious problem - resolve or explain

0 ALERT level B = A potentially serious problem, consider carefully

7 ALERT level C = Check. Ensure it is not caused by an omission or oversight

41 ALERT level G = General information/check it is not something unexpected

5 ALERT type 1 CIF construction/syntax error, inconsistent or missing data

13 ALERT type 2 Indicator that the structure model may be wrong or deficient

7 ALERT type 3 Indicator that the structure quality may be low

21 ALERT type 4 Improvement, methodology, query or suggestion

2 ALERT type 5 Informative message, check

## References

1. N. Rastogi, I.N.N. Namboothiri, M. Cojocaru, *Tetrahedron Letters*, 2004, **45**, 4745-4748.
2. I. Deb, M. Dadwal, M. Mobin and I. N. N. Namboothiri, *Org. Lett.* 2006, **8**, 1201–1204.
3. R. Maity, C. Gharui, A. Sil, S. Pan, *Org. Lett.*, 2017, **19**, 662–665.